Get the Stockscreener App
16.08
3.25%
-0.54
After Hours:
16.05
-0.03
-0.19%
Immunovant Inc stock is traded at $16.08, with a volume of 1.13M.
It is down -3.25% in the last 24 hours and up +0.50% over the past month.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.
See More
Previous Close:
$16.62
Open:
$16.44
24h Volume:
1.13M
Relative Volume:
0.88
Market Cap:
$2.75B
Revenue:
-
Net Income/Loss:
$-382.71M
P/E Ratio:
-6.1374
EPS:
-2.62
Net Cash Flow:
$-325.64M
1W Performance:
-12.23%
1M Performance:
+0.50%
6M Performance:
-26.03%
1Y Performance:
-44.69%
1-Day Range:
$15.84
$16.66
1-Week Range:
$15.31
$17.49
52-Week Range:
$12.72
$34.47
Immunovant Inc Stock (IMVT) Company Profile
Name
Immunovant Inc
Sector
Industry
Phone
917-580-3099
Address
320 WEST 37TH STREET, NEW YORK, NY
Compare IMVT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMVT
Immunovant Inc
|
16.08 | 2.84B | 0 | -382.71M | -325.64M | -2.62 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Immunovant Inc Stock (IMVT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Resumed | Goldman | Neutral |
| Mar-03-25 | Initiated | Jefferies | Hold |
| Jan-03-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Oct-09-24 | Reiterated | Oppenheimer | Outperform |
| Mar-28-24 | Initiated | Oppenheimer | Outperform |
| Mar-13-24 | Initiated | Goldman | Buy |
| Feb-20-24 | Initiated | JP Morgan | Overweight |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Oct-13-23 | Upgrade | UBS | Neutral → Buy |
| Sep-26-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-01-23 | Initiated | BofA Securities | Buy |
| Apr-25-23 | Initiated | Citigroup | Buy |
| Mar-31-23 | Initiated | Piper Sandler | Overweight |
| Mar-30-23 | Initiated | Stifel | Buy |
| Feb-15-23 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-13-23 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-03-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Sep-26-22 | Downgrade | UBS | Buy → Neutral |
| Dec-08-21 | Initiated | Wells Fargo | Equal Weight |
| Aug-03-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Aug-02-21 | Downgrade | Credit Suisse | Neutral → Underperform |
| Jun-01-21 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-01-21 | Downgrade | Stifel | Buy → Hold |
| Oct-28-20 | Initiated | UBS | Buy |
| Oct-12-20 | Initiated | Guggenheim | Buy |
| Oct-08-20 | Initiated | Stifel | Buy |
| Oct-02-20 | Initiated | Credit Suisse | Outperform |
| Aug-26-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Jul-29-20 | Initiated | H.C. Wainwright | Buy |
| Feb-24-20 | Initiated | SVB Leerink | Outperform |
View All
Immunovant Inc Stock (IMVT) Latest News
Is it the right time to buy Immunovant Inc. stockAI Powered Updates From AI Tools - jammulinksnews.com
What makes Immunovant Inc. stock price move sharplyBest Dividend Outlook For Consistent Profits - jammulinksnews.com
When is Immunovant Inc. stock expected to show significant growthChart Pattern Opportunities With High Returns - jammulinksnews.com
How many analysts rate Immunovant Inc. as a “Buy”AI Powered Tips For 2025 - jammulinksnews.com
Immunovant appoints Eric Venker as CEO with new compensation agreement - Investing.com Australia
Immunovant Appoints Eric Venker as New CEO - TipRanks
Momentum Screeners Rank Immunovant Inc. in Top 5 TodayReversal Alert Based on RSI Indicator Confirmed - metal.it
Immunovant Inc. Hits Oversold Level on RSI IndicatorProfit Focused Stock Screener Results Released - metal.it
Is Immunovant Inc. stock overvalued or undervaluedEntry Signal Forecasts For Consistent Profits - jammulinksnews.com
Immunovant Inc. stock volume spike explainedFree Fast Return Equity Trade Forecast - Newser
Immunovant Inc. stock daily chart insightsFree Risk Controlled Short Term Trade Plans - Newser
Can momentum traders help lift Immunovant Inc.Chart Driven Entry Timing for Swing Trades - Newser
How volatile is Immunovant Inc. stock compared to the marketDiscover stocks with explosive growth potential - jammulinksnews.com
What are analysts’ price targets for Immunovant Inc. in the next 12 monthsRapid-fire capital growth - jammulinksnews.com
Immunovant Inc. Company Revenue and Profit Trends: A Deep DiveFree Real-Time Stock Data - metal.it
What institutional investors are buying Immunovant Inc. stockNavigate the market with precision tools - jammulinksnews.com
What is the dividend policy of Immunovant Inc. stockInvest smarter with real-time trading signals - jammulinksnews.com
Immunovant (IMVT) Gets a Buy from Cantor Fitzgerald - The Globe and Mail
Bank of New York Mellon Corp Reduces Holdings in Immunovant, Inc. (NASDAQ:IMVT) - Defense World
Immunovant Executives Sell Shares to Cover Tax Obligations - TradingView
Can Immunovant Inc. stock recover from recent declineHigh-profit stock alerts - jammulinksnews.com
LifeSci Capital Maintains a Buy on Immunovant (IMVT) With a $50 PT - MSN
Is Immunovant Inc. a good long term investmentExceptional gains - PrintWeekIndia
What drives Immunovant Inc. stock priceHigh-profit stock alerts - Autocar Professional
What analysts say about Immunovant Inc. stockTremendous wealth creation - Autocar Professional
Why Immunovant Inc. stock attracts strong analyst attentionFree Daily Stock Market Updates - Newser
How high can Immunovant Inc. stock price go in 2025Free Smart Trading Workshop - jammulinksnews.com
Immunovant, Inc. (NASDAQ:IMVT) Shares Purchased by Arizona State Retirement System - Defense World
Immunovant Inc. Stock Analysis and ForecastRecord-setting profit potential - jammulinksnews.com
We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely - 富途牛牛
Teacher Retirement System of Texas Buys 2,919 Shares of Immunovant, Inc. (NASDAQ:IMVT) - Defense World
why immunovant inc. stock attracts strong analyst attentionFree Access to Community - Newser
September 19th Options Now Available For Immunovant (IMVT) - Nasdaq
Immunovant Inc Stock (IMVT) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):